Mylan Increases Injectable Presence, But In Declining Market
This article was originally published in PharmAsia News
The generics company added to its arsenal of injectable drugs by acquiring rights to Aspen’s DVT treatment Arixtra, but the anticoagulant faces tough competition from oral entrants.
You may also be interested in...
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
Both Valeant and Mylan faced pointed questions from analysts on their year-end calls about consolidation in the industry and plans for further M&A.
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.